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Purpose: To examine the effect of the type and the concentration of neutron capture agents on the values of
compound biological effectiveness (CBE) in boron neutron capture therapy.
Methods and materials: After the subcutaneous administration of a 10B-carrier, boronophenylalanine-10B (BPA) or
sodium mercaptododecaborate-10B (BSH), at 3 separate concentrations, the 10B concentrations in tumors were
measured by γ-ray spectrometry. SCC VII tumor-bearing C3H/He mice received 5-bromo-2′-deoxyuridine (BrdU)
continuously to label all intratumor proliferating (P) cells, then treated with BPA or BSH. Immediately after reactor
neutron beam irradiation, during which intratumor 10B concentrations were kept at levels similar to each other, cells
from some tumors were isolated and incubated with a cytokinesis blocker. The responses of BrdU-unlabeled
quiescent (Q) and total (= P + Q) tumor cells were assessed based on the frequencies of micronucleation using
immunofluorescence staining for BrdU.
Results: The CBE values were higher in Q cells and in the use of BPA than total cells and BSH, respectively. In
addition, the higher the administered concentrations were, the smaller the CBE values became, with a clearer
tendency in the use of BPA than BSH. The values for neutron capture agents that deliver into solid tumors more
dependently on uptake capacity of tumor cells became more changeable.
Conclusion: Tumor characteristics, such as micro-environmental heterogeneity, stochastic genetic or epigenetic
changes, or hierarchical organization of tumor cells, are thought to partially influence on the value of CBE, meaning
that the CBE value itself may be one of the indices showing the degree of tumor heterogeneity.
Keywords: Boron neutron capture therapy; Neutron capture agent; Relative biological effectiveness; Compound
biological effectiveness; Tumor heterogeneity; Quiescent cellIntroduction
A neutron capture reaction in boron [10B(n, α)7Li] is, in
principle, very effective in destroying tumors, provided
that a sufficient amount of 10B can be accumulated in
the target tumor and a sufficient number of very-low-
energy thermal neutrons can be delivered there. The two
particles generated in this reaction have a high linear* Correspondence: smasuna@rri.kyoto-u.ac.jp
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in any medium, provided the original work is penergy transfer (LET) and have a range of roughly the
diameter of one or two tumor cells. It is theoretically
possible to kill tumor cells without affecting adjacent
healthy cells, if 10B atoms can be selectively accumulated
in the interstitial space of tumor tissue and/or intracellular
space of tumor cells. Thus, successful boron neutron cap-
ture therapy (BNCT) requires the selective delivery of
large amounts of 10B to malignant cells (Barth et al. 2005).
The greater density of ionizations along high LET
particle tracks results in an increased biological effect
compared with the same physical dose of low LETis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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(RBE), which is the ratio of the absorbed dose of a ref-
erence source of radiation (e.g., X-rays) to that of the
test radiation that produces the same biological effect.
Because both tumor and surrounding normal tissues are
present in the radiation field, there will be an unavoidable,
nonspecific background dose, consisting of both high and
low LET radiation. However, a greater concentration of
10B in the tumor will result in receiving a much higher
total dose than that of adjacent normal tissues. This is the
basis for the therapeutic gain in BNCT. The total radiation
dose delivered to any tissue can be expressed in photon
equivalent units as the sum of each of the high LET dose
components multiplied by weighting factors, which de-
pend on the increased radiobiological effectiveness of each
of these radiation components (Barth et al. 2012).
The dependence of the biological effect on the micro-
distribution of 10B requires the use of a more appropriate
term than RBE to define the biological effects through
the 10B(n,α)7Li reaction. Measured biological effective-
ness factors for the components of the dose from this
reaction have been originally introduced by Gahbauer
et al. as the “compound factors” (Gahbauer et al. 1989;
Gupta et al. 1994). Subsequently, the factors have been
called “compound biological effectiveness (CBE) factors”
(Hopewell et al. 2011; Hopewell et al. 2012). The mode
and route of the administration of a 10B-carrier, the 10B
distribution within the tumor, normal tissues, and even
more specifically within cells, and even the size of the nu-
cleus within the target cell population, can all influence
the experimental determination of the CBE factor. CBE
factors are fundamentally different from the classically
defined RBE, which is primarily dependent on the quality
(i.e., LET) of the radiation administered. CBE factors are
strongly influenced by the distribution of the specific 10B
delivery agent and can differ substantially, although they
all describe the combined effects of α particles and 7Li
ions. The CBE factors for the 10B component of the dose
are specific for both the 10B delivery agent and the tissue.
A weighted Gy unit [Gy(w)] has been used to express the
summation of all BNCT dose components and indicates
that the appropriate RBE and CBE factors have been ap-
plied to the high LET dose components. However, for
clinical BNCT, the overall calculation of photon equivalent
[Gy(w)] doses requires several assumptions about RBEs,
CBE factors, and the 10B concentrations in various tissues,
based on currently available human or experimental data
(Hopewell et al. 2011; Hopewell et al. 2012).
Here, we tried to analyze the changes in the values of
RBE for neutron only irradiation and CBE factors for
employed 10B-carriers according to their concentra-
tions when administered in vivo. The neutron capture
reaction was performed with two 10B-carriers, boro
nophenylalanine-10B (BPA, C9H12
10BNO4) and sodiummercaptoundecahydrododecaborate-10B (sodium borocaptate-
10B, BSH, Na2
10B12H11SH). Regarding the local tumor re-
sponse, the effect not only on the total (= proliferating
(P) + quiescent (Q)) tumor cell population, but also on
the Q cell population, was evaluated using our original
method for selectively detecting the response of Q cells
in solid tumors (Masunaga and Ono 2002).
Materials and methods
Mice and tumors
SCC VII squamous cell carcinomas (Department of
Radiology, Kyoto University) derived from C3H/He mice
were maintained in vitro in Eagle’s minimum essential
medium supplemented with 12.5% fetal bovine serum.
Cells were collected from exponentially growing cultures,
and 1.0 × 105 cells of each tumor were inoculated sub-
cutaneously into the left hind legs of 8- to 11-week-old
syngeneic female C3H/He mice (Japan Animal Co., Ltd.,
Osaka, Japan). Fourteen days after the inoculation, each
tumor had reached approximately 1 cm in diameter. At
treatment, the body weight of the tumor-bearing mice
was 22.1 ± 2.3 (mean ± standard deviation) g. Mice were
handled according to the Recommendations for Handling
of Laboratory Animals for Biomedical Research, compiled
by the Committee on Safety and Ethical Handling Regula-
tions for Laboratory Animal Experiments, Kyoto University.
All experimental procedures mentioned here were in
accordance with institutional guidelines for the care and
use of laboratory animals in research.
Compounds
BPA and BSH were purchased from Katchem spol. s.r.o.
(Czech Republic). BPA was converted to a fructose
complex to increase its solubility following the method
reported by Coderre et al. (Coderre et al. 1994). The
aqueous solution of BPA was prepared at a concentra-
tion of 250, 500, or 750 mg·kg−1. BSH dissolved in
physiological (0.9%) saline was prepared at a concentration
of 125, 250, or 375 mg·kg−1. In accordance with our previ-
ous studies (Masunaga et al. 2001), at a dose of less than
1,500 mg·kg−1for BPA and less than 500 mg·kg−1for BSH,
no overt toxicity was observed. Based on the certificate of
analysis and Material Safety Data Sheet provided by the
manufacturer, it was not contaminated with the borocap-
atate dimer (BSSB, [10B24H22S2]
4−).
Biodistribution experiment
10B-carrier solution was administered to the tumor-
bearing mice subcutaneously into nuchal sites in a volume
of 0.02 mL·g−1 per mouse body weight. Doses of 250, 500,
or 750 mg·kg−1 of BPA are equal to 12.0, 24.0 and 36.0 mg
10B·kg−1. Doses of 125, 250, or 375 mg·kg−1 of BSH are
equal to 71.0, 142.0 and 213.0 mg 10B·kg−1. At various
time points after the administration through subcutaneous
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mors were excised. Additionally, blood samples were col-
lected through heart puncture. The 10B concentrations in
these tissues were measured by prompt γ-ray spectrom-
etry using a thermal neutron guide tube installed at the
Kyoto University Reactor (KUR) (Kobayashi and Kanda
1983).
Labeling with 5-bromo-2′-deoxyuridine (BrdU)
Nine days after the tumor cell inoculation, mini-osmotic
pumps (Durect Corporation, Cupertino, CA, USA) contain-
ing BrdU dissolved in physiological saline (200-250 mg·ml−1)
were implanted subcutaneously, to label all P cells, for 5
days. Administration of BrdU did not change the tumor
growth rate. The tumors were 1 cm in diameter at treat-
ment. The labeling index after continuous labeling with
BrdU was 55.3 ± 4.5 (mean ± standard deviation) %, and
reached a plateau level at these stages. Therefore, we
regarded tumor cells not incorporating BrdU after con-
tinuous labeling as Q cells.
Irradiation
Since the intratumor 10B concentration during neutron
irradiation is a crucial determinant for the cell-kill effect
in BNCT, irradiation was started at selected time points
after the subcutaneous injection of the 10B-carriers at a
selected dose of 10B. Based on a preliminary study of the
biodistribution of 10B, irradiation was started from 60 min
after the subcutaneous injection, and finished by 180 min
after the injection.
To irradiate the tumors implanted into the left hind legs
of mice, a device made of acrylic resin and capable of
holding 12 mice was used, and the tumor-bearing mice
were irradiated with a reactor neutron beam at a power of
1 MW at KUR or γ-rays after being fixed in position with
adhesive tape. A lithium fluoride (LiF) thermoplastic
shield was employed to avoid irradiating other body parts
except implanted solid tumors. Neutron irradiation was
performed using a reactor neutron beam with a cadmium
ratio of 9.4. The neutron fluence was measured from the
radioactivation of gold foil at both the front and back of
the tumors. Since the tumors were small and located just
beneath the surface, the neutron fluence was assumed to
decrease linearly from the front to back of the tumors.
Thus, we used the average neutron fluence determined
from the values measured at the front and back. Contam-
inating γ-rays, including secondary γ-rays, doses were
measured with a thermoluminescence dosimeter (TLD)
powder at the back of the tumors. The used TLD was
beryllium oxide (BeO) enclosed in a quartz glass capsule.
BeO itself has a fairly strong sensitivity to thermal neu-
trons. The thermal neutron fluence of 8 × 1012 cm−2 is
equal to an approximately 1 cGy γ-ray dose. We usually
use the TLD together with gold activation foil forneutron-sensitivity correction. The details were described
in the following reference (Sakurai and Kobayashi 2000).
To estimate neutron energy spectra, eight kinds of activa-
tion foil and fourteen kinds of nuclear reaction were used
(Sakurai and Kobayashi 2000). The absorbed dose was cal-
culated using the flux-to-dose conversion factor (Kobayashi
et al. 2000). The tumors contained H (10.7 % in terms
of weight), C (12.1 %), N (2 %), O (71.4 %), and other el-
ements (3.8 %) (Snyder et al. 1975). The average neu-
tron flux and Kerma rate of the employed beams were
1.0 × 109 n·cm−2·s−1 and 48.0 cGy·h−1 for the thermal
neutron range (less than 0.6 eV), 1.6 × 108 n·cm−2·s−1 and
4.6 cGy·h−1 for the epithermal neutron range (0.6 through
10 keV), and 9.4 × 106 n·cm−2·s−1and 32.0 cGy·h−1 for the
fast neutron range (more than 10 keV), respectively.
The Kerma rate for the boron dose per Φ n·cm−2·s−1
of thermal neutron flux for 1 μg·g−1 of 10B was 2.67 ×
10−8 Φ cGy·h−1. The dose rate of γ-rays including con-
taminating γ-rays in reactor neutron beams and γ-rays
resulting from capture of thermal neutrons by hydro-
gen atoms [1H(n,γ)2H] was 66.0 cGy·h−1. Irradiation
with γ-rays was performed with a cobalt-60 γ-ray irra-
diator at a dose rate of approximately 2.0 Gy·min−1.
Each irradiation group also included mice that were
not pretreated with BrdU.Immunofluorescence staining of BrdU-labeled cells and
micronucleus assay
Right after the in vivo irradiation of the implanted tumors,
tumors were excised from the mice given BrdU, minced,
and trypsinized (0.05% trypsin and 0.02% ethylenediamine-
tetraacetic acid (EDTA) in phosphate-buffered saline [PBS],
37°C, 15 min). Tumor cell suspensions thus obtained
were incubated for 72 h in tissue culture dishes contain-
ing complete medium and 1.0 μg·ml−1 of cytochalasin-B
to inhibit cytokinesis while allowing nuclear division,
and the cultures were then trypsinized and cell suspen-
sions were fixed. After the centrifugation of fixed cell
suspensions, each cell pellet was resuspended with cold
Carnoy’s fixative (ethanol:acetic acid = 3:1 in volume).
The suspension was then placed on a glass microscope
slide and the sample was dried at room temperature.
The slides were treated with 2M hydrochloric acid for
60 min at room temperature to dissociate the histones
and partially denature the DNA. The slides were then
immersed in borax-borate buffer (pH 8.5) to neutralize
the acid. BrdU-labeled tumor cells were detected by in-
direct immunofluorescence staining using a monoclonal
anti-BrdU antibody (Becton Dickinson, San Jose, CA,
USA) and a fluorescein isothiocyanate (FITC)-conjugated
antimouse IgG antibody (Sigma, St. Louis, MO, USA).
To observe the double staining of tumor cells with
green-emitting FITC and red-emitting propidium iodide
Table 1 Surviving fraction and micronucleus frequency at
0 Gy
Total tumor cells Quiescent cells
<Plating efficiency (%)>
Without 10B-carrier 70.7 ± 8.8a ——
BPAb (250 mg/kg) 45.5 ± 5.8 ——
BPA (500 mg/kg) 40.5 ± 4.6 ——
BPA (750 mg/kg) 39.4 ± 3.8 ——
BSHc (125 mg/kg) 54.0 ± 6.8 ——
BSH (250 mg/kg) 50.0 ± 5.8 ——
BSH (325 mg/kg) 44.8 ± 4.8 ——
<Micronucleus frequency>
Without 10B-carrier 0.029 ± 0.007 0.053 ± 0.007
BPA (250 mg/kg) 0.045 ± 0.010 0.067 ± 0.008
BPA (500 mg/kg) 0.050 ± 0.011 0.073 ± 0.009
BPA (750 mg/kg) 0.054 ± 0.012 0.078 ± 0.012
BSH (125 mg/kg) 0.042 ± 0.005 0.069 ± 0.011
BSH (250 mg/kg) 0.047 ± 0.005 0.075 ± 0.010
BSH (325 mg/kg) 0.052 ± 0.007 0.081 ± 0.012
a; Mean ± standard error (n = 9).
b; Boronophenylalanine-10B.
c; Sodium mercaptododecaborate-10B.
The values of the plating efficiencies and micronucleus frequencies for the
combination with the 10B-carrier were significantly lower and higher than
those for no combination with the 10B-carrier, respectively.
The values of the micronucleus frequencies for quiescent cells were
significantly higher than those for total tumor cells.
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PBS) and monitored under a fluorescence microscope.
When cell division is disrupted, or the chromosomes are
broken or damaged by chemicals or radiation, then the
distribution of genetic material between the two daughter
nuclei during cell division is affected and pieces or entire
chromosomes fail to be included in either of the two
daughter nuclei. The genetic material that is not incorpo-
rated into a new nucleus forms its “micronucleus (MN)”.
Thus, the frequency of micronucleus formation very well
reflects the genotoxicity of a chemical compound and
radiation. The MN frequency in cells not labeled with
BrdU could be examined by counting the micronuclei
in the binuclear cells that showed only red fluorescence.
The MN frequency was defined as the ratio of the number
of micronuclei in the binuclear cells to the total number
of binuclear cells observed. The ratios obtained in tumors
not pretreated with BrdU indicated the MN frequency at
all phases in the total (P +Q) tumor cell population. More
than 400 binuclear cells were counted to determine the
MN frequency (Masunaga and Ono 2002).
Clonogenic cell survival assay
A clonogenic cell survival assay was also performed
in the mice given no BrdU using an in vivo-in vitro
assay method. Tumors were disaggregated by stirring
for 20 min at 37°C in PBS containing 0.05% trypsin and
0.02% EDTA. The cell yield was (4.5 ± 0.9) × 107 g−1 per
tumor weight. Appropriate numbers of viable tumor cells
from the single cell suspension were plated on 60 or 100
mm tissue culture dishes, and, 12 days later, colonies were
fixed with ethanol, stained with Giemsa, and counted. For
the tumors that received no irradiation, the plating effi-
ciencies (PEs) for the total tumor cell populations and
the MN frequencies for the total and Q cell populations
are shown in Table 1.
Three mice were used to assess each set of conditions
and each experiment was repeated twice. To examine the
differences between pairs of values, the Student’s t-test
was used when variances of the two groups could be
assumed to be equal; otherwise, the Welch t-test was
used. P-values are from two-sided tests.
Results
Based on the data in Table 1, BPA or BSH treatment in-
duced a significantly lower PE and higher MN frequency
in both the Q and total cell populations (P < 0.05) than
no drug treatment. Q cells showed significantly higher
MN frequencies than the total cell population under
each set of conditions (P < 0.05). Further, although not
significantly, as the administered doses of 10B-carriers
increased, the changes in the PE and MN frequency
tended to become more remarkable compared with no
drug treatment.Figure 1(a) and (b) show the time course of change in
the values of the 10B concentration in solid tumors and
blood, respectively. On the whole, the concentrations of
10B from both 10B-carriers, especially from BSH, in blood
were higher than those in the tumors, and 10B from BSH
in blood, that was higher than that from BPA, washed
away much more rapidly than that from BPA. In contrast,
the retention of 10B from the 10B-carriers in the tumors
was similar except at 30 min after administration, when the
concentration of 10B from BSH was much higher than that
from BPA. As the administered doses of the 10B-carriers in-
creased, higher concentrations of 10B in tumors and blood
were observed. The 10B concentrations shown here were
not thought to be especially toxic (Masunaga et al. 2004).
Based on the findings concerning these 10B biodistri-
bution patterns, irradiation was started from 60 min
and was finished by 180 min after the subcutaneous ad-
ministration of the 10B-carriers, because it took ap-
proximately 60 through 120 min to deliver a sufficient
physical dose of radiation to solid tumors with reactor
neutron beams. The 10B concentrations during irradi-
ation in tumors for BPA administration at the doses of
250, 500 and 750 mg·kg−1 were 17.5 ± 1.7 μg·g−1, 22.5 ±
6.9 μg·g−1 and 25.0 ± 5.2 μg·g−1, respectively. The 10B
concentrations during irradiation in tumors for BSH
Figure 1 Time course of changes in 10B concentrations in the solid tumors (a) and blood collected from the hearts (b) of SCC VII
tumor-bearing mice after subcutaneous administration of each 10B-carrier. Left panel of (a) shows time course of changes in tumors
following administration of boronophenylalanine-10B at doses of 250 (●), 500 (▲), or 750 (■) mg·kg−1. Right panel of (a) shows time course of
changes in tumors following administration of sodium mercaptododecaborate-10B at doses of 125 (●), 250 (▲), or 375 (■) mg·kg−1. (b) shows
time course of changes in blood following administration of each 10B-carrier. Solid lines represent boronophenylalanine-10B at the doses of 250
(○), 500 (△), or 750 (□) mg·kg−1. Dotted lines represent sodium mercaptododecaborate-10B at doses of 125 (○), 250 (△), or 375 (□) mg·kg−1. Bars
represent standard errors.
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were 17.3 ± 1.7 μg·g−1, 22.2 ± 6.9 μg·g−1 and 25.7 ± 5.0 μg·g−1,
respectively.
When neutron beams were employed, radiation dose
means the physical radiation dose due to energy depos-
ition from 3 types of radiation: (a) low LET γ-rays
resulting from capture of thermal neutrons by hydrogen
atoms [1H(n,γ)2H], and from the contaminating exter-
nal γ-rays originally included in the employed neutron
beams; (b) high LET protons produced by the scattering
of fast neutrons and from capture of thermal neutrons
by nitrogen atoms [14N(n,p)14C]; and (c) high LET, heavier-
charged α particles and 7Li ions released as products of
the thermal neutron capture and fission reactions with
10B [10B(n,α)7Li] in the presence of 10B.
The data on cell survival following γ-ray irradiation
only were fitted to the linear quadratic (LQ) dose rela-
tionship (Hall 2012). The clonogenic cell survival curves
after in vivo irradiation using reactor neutron beams fol-
lowing administration of the 10B-carrier were obtained
as the cell survival curves for “neutron beams”. When
reactor neutron beams were employed for irradiation,
the data on cell survival following reactor neutron beam
irradiation were normalized with the data on cell sur-
vival for γ-ray irradiation only by dividing the data for
neutron beams by the data for γ-ray irradiation only in
order to obtain the data on cell survival for irradiation
with “neutrons only” (Hopewell et al. 2012; Hall 2012).
At this normalization, the dose reduction factor for γ-rays
of 0.45 was taken into consideration because the γ-ray
dose rate of employed neutron beams was much less than
1 Gy·min−1, that is, 0.011 Gy·min−1 (Hopewell et al. 2011;
Hopewell et al. 2012). Similarly, the data on cell survival
for irradiation with “neutrons only” without administrationof the 10B-carrier were fitted to the LQ dose relationship.
Further, when reactor neutron beams were employed for
irradiation following administration of the 10B-carrier, the
data on cell survival for irradiation with “neutrons only”
with the administration of the 10B-carrier were normal-
ized with the data on cell survival for irradiation with
“neutrons only” without the administration of the 10B-
carrier by dividing the data for “neutrons only” with the
10B-carrier by the data for irradiation with “neutrons only”
without the 10B-carrier in order to obtain data on cell
survival for irradiation at the “10B dose”.
When the 10B-carrier was employed, even if no radiation
was given, MN frequencies were higher than when no
10B-carrier was administered because of the slight geno-
toxicity of the drug (Table 1). Therefore, for background
correction, we used the net MN frequency to exclude the
effects of the genotoxicity of the 10B-carrier. The net
frequency is the frequency in the irradiated tumors minus
the frequency in the nonirradiated tumors.
The data on net MN frequency following γ-ray irradi-
ation only were also fitted to the linear quadratic (LQ)
dose relationship (Hall 2012). The dose-response curves
of the net MN frequency after in vivo irradiation using
reactor neutron beams following administration of the
10B-carrier were obtained as the dose-response curves of
net MN frequencies for “neutron beams”. When reactor
neutron beams were employed for irradiation, the data
on the net MN frequency following reactor neutron
beam irradiation were normalized with the data on the
net MN frequency for γ-ray irradiation only by subtract-
ing the data for γ-ray irradiation only from the data for
neutron beams in order to obtain the data on the net
MN frequency for irradiation with “neutrons only”. At
this normalization, the dose reduction factor for γ-rays
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data on the net MN frequency for irradiation with “neu-
trons only” without administration of the 10B-carrier
were fitted to the LQ dose relationship. Further, when
reactor neutron beams were employed for irradiation
following administration of the 10B-carrier, the data on
the net MN frequency for irradiation with “neutrons
only” with the administration of the 10B-carrier were
normalized with the data on the net MN frequency for
irradiation with “neutrons only” without the administra-
tion of the 10B-carrier by subtracting the data for irradi-
ation with “neutrons only” without the 10B-carrier from
the data for “neutrons only” with the 10B-carrier in order
to obtain data on the net MN frequency for irradiation
at the “10B dose” (Hopewell et al. 2011; Hopewell et al.
2012; Coderre et al. 2003).
Figure 2 shows the clonogenic cell survival curve and
the net MN frequencies after in vivo irradiation using
γ-rays only, respectively. The surviving fraction (SF) was
expressed as a function of ln SF = - 0.125 D – 0.0018 D2
(D: delivered radiation dose (Gy)). The net MN frequen-
cies for Q cells were significantly lower than those for total
tumor cells (P < 0.05). The net MN frequencies for total
and Q tumor cells were expressed as a function of Net
MN frT = 0.042 D + 0.0006 D
2 and Net MN frQ = 0.0205
D + 0.0003 D2, respectively.
Figure 3(a) and (b) show cell survival curves and the net
MN frequencies after in vivo irradiation using neutron
beams without the 10B-carrier, respectively. In terms of
the net MN frequency, the difference in radio-sensitivity
between total and Q tumor cells was apparently reduced
compared with irradiation with γ-rays only. To obtain data
on cell survival and the net MN frequency for “neutrons
only” without the 10B-carrier, the data for “neutron beams”
without the 10B-carrier were normalized with the above-Figure 2 Left and right panels show cell survival curves and the net m
only, respectively, as a function of the physical radiation dose in tota
populations. Bars represent standard errors (n = 9).mentioned data for irradiation with γ-rays only. The cell
survival for “neutrons only” without the 10B-carrier was
expressed as a function of ln SF = - 0.3384 D – 0.0121 D2.
The net MN frequencies for “neutrons only” without the
10B-carrier in total and Q tumor cells were expressed as a
function of Net MN frT = 0.1119 D + 0.0074 D
2 and Net
MN frQ = 0.0837 D + 0.0135 D
2, respectively.
The data on cell survival and the net MN frequency
for irradiation with “neutron beams” with the 10B-carrier
were normalized with the data for irradiation with γ-rays
only, then further normalized with the data for irradiation
with “neutrons only” without the 10B-carrier in order to
obtain data for irradiation at the “10B dose”. Figure 4(a)
and (b) show cell survival curves and the net MN frequen-
cies in the function of physically absorbed radiation dose
after in vivo irradiation using neutron beams following
BPA administration, respectively. Figure 5(a) and (b) show
cell survival curves and the net MN frequencies in the
function of physically absorbed radiation dose after in vivo
irradiation using neutron beams following BSH adminis-
tration, respectively. In Figures 4 and 5, the data for irradi-
ation with available reactor “neutron beams” including
γ-rays, with “neutrons only” excluding contribution of
γ-rays, and with “10B dose” further excluding contribu-
tion of neutrons in the absence of 10B, that is to say, the
physically absorbed dose truly originating from high
LET, heavier-charged α particles and 7Li ions released
as products of the thermal neutron capture and fission
reactions with 10B [10B(n,α)7Li] only in the presence of
10B are shown left, central and right panels, respectively.
Whichever 10B-carrier was employed, the radio-sensitivity
was decreased as the concentration of administered
10B-carrier increased. In addition, this tendency was more
clearly observed when using BPA than BSH and in Q than
in the total tumor cell population.icronucleus (MN) frequencies after in vivo irradiation with γ-rays
l (open symbols) and quiescent (Q, (solid symbols)) tumor cell
Figure 3 Cell survival curves (a) and the net micronucleus (MN) frequencies (b) after in vivo irradiation using neutron beams without
the 10B-carrier as a function of the physical radiation dose in total (open symbols) and quiescent (Q, (solid symbols)) tumor cell
populations. The data for irradiation with reactor “neutron beams” and with “neutrons only” are shown at left and right panels, respectively. Bars
represent standard errors (n = 9).
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10B-carrier and the CBE factors for BPA and BSH at
each administered concentration in both total and Q
cell populations compared with γ-rays, the data given in
Figures 2, 3, 4 and 5 were used (Table 2). Overall, the
values for Q cells were significantly higher than those
for total cells (P < 0.05). In total and Q tumor cell popu-
lations, BPA showed higher and lower values of the
CBE factors than BSH, respectively. The values of the
CBE factors for both 10B-carriers tended to decrease as
the administered concentrations increased, especially
those for BPA.
To examine the difference in radio-sensitivity between
the total and Q cell populations, dose-modifying factorswere calculated using the data in Figures 2 and 5 (Table 3).
All the values were significantly larger than 1.0. The differ-
ence in radio-sensitivity under γ-ray irradiation was de-
creased when using neutron beams alone. The difference
in sensitivity decreased in the following order; γ-rays only
> neutrons with BPA > neutrons with BSH > neutrons
only. Further, whichever 10B-carrier was employed, the dif-
ference in sensitivity tended to increase as the concentra-
tion of the administered 10B-carrier increased.
Discussion
We administered the 10B-carrier not intraperitoneally
but subcutaneously since high 10B concentration in tu-
mors was thought to be able to be kept as long as
Figure 4 Cell survival curves (a) and the net micronucleus frequencies (b) after in vivo irradiation using neutron beams following
subcutaneous administration of boronophenylalanine-10B at dose of 250 (circles), 500 (triangles), or 750 (squares) mg·kg-1 as a
function of the physical radiation dose in total (open symbols) and quiescent (Q, (solid symbols)) tumor cell populations. The data for
irradiation with reactor “neutron beams”, with “neutrons only”, and at the “10B dose” are shown at the left, central, and right panels, respectively.
Bars represent standard errors (n = 9).
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http://www.springerplus.com/content/3/1/128possible compared with intraperitoneal administration.
Actually, which 10B-carrier was employed, the decreas-
ing pattern of 10B concentration in tumors was not so
rapid as intraperitoneal administration (Masunaga et al.
2004). The biodistribution patterns in SCC VII tumors
as a whole of 10B from subcutaneously administered
BPA at doses of 250, 500 and 750 mg·kg−1 were very
similar to those from BSH at doses of 125, 250, and 375
mg·kg−1 , respectively, except at 30 min after administra-
tion, when the concentration of 10B from BSH was much
higher than that from BPA. Therefore, the 10B concen-
trations during irradiation, which was started from 60
min and finished by 180 min after administration, in tu-
mors for BPA administration at doses of 250, 500 and
750 mg·kg−1 were also very similar to those for BSH ad-
ministration at doses of 125, 250 and 375 mg·kg−1, re-
spectively. This is probably because the tumor
distribution of 10B from BSH is mostly dependent on the
diffusion of the drug, whereas that from BPA is moredependent on the ability of the tumors to take up 10B
(Masunaga and Ono 2002). This is also thought to sup-
port the finding that 10B from BSH in blood, that was
higher than that from BPA, washed away more rapidly
than that from BPA.
Solid tumors, especially human tumors, are thought to
contain a high proportion of Q cells [14]. The presence
of Q cells is probably due, in part, to hypoxia and the
depletion of nutrients in the tumor core, another conse-
quence of poor vascular supply (Vaupel 2004). This may
promote the formation of micronuclei at 0 Gy in Q
tumor cells (Table 1) and induce a higher level of tumor
heterogeneity in Q than P tumor cells (Vaupel 2004). Q
cells were shown to have significantly less radio-sensitivity
than the total cells here (Figure 2). This means that more
Q cells survive radiation therapy than P cells. Thus, the
control of Q cells has a great impact on the outcome of
radiation therapy. The frequency of closely spaced DNA
lesions forming a cluster of DNA damage produced by
Figure 5 Cell survival curves (a) and the net micronucleus frequencies (b) after in vivo irradiation using neutron beams following
subcutaneous administration of sodium mercaptododecaborate-10B at dose of 125 (circles), 250 (triangles), or 375 (squares) mg·kg-1 as
a function of the physical radiation dose in total (open symbols) and quiescent (Q, (solid symbols)) tumor cell populations. The data for
irradiation with reactor “neutron beams”, with “neutrons only”, and at the “10B dose” are shown at the left, central, and right panels, respectively.
Bars represent standard errors (n = 9).
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http://www.springerplus.com/content/3/1/128high LET radiation is thought to be much less dependent
on oxygenation status at the time of irradiation than that
of DNA damage produced by low LET γ-ray irradiation
(Hamada et al. 2010). Accordingly, in both the total and
Q cell populations, neutron only irradiation was less
dependent on oxygenation status, leading to much
higher RBE values compared with γ-ray irradiation in Q
than the total tumor cell population (Table 2) (Hamada
et al. 2010). In terms of the tumor cell-killing effect as a
whole, including intratumor Q cell control, neutron
only beam radiotherapy is a promising treatment for
refractory tumors.
Actually, BNCT is a mixed field irradiation. The princi-
pal dose components, in addition to the α-particles and
7Li ions resulting from the boron capture reaction: 10B +
1n = 7Li + 4He(α) + 2.79 MeV include γ-rays (dγ), both
incident within the neutron beam and induced by the
neutron capture reaction in hydrogen: 1H+ 1n = 2H+ γ +
2.2 MeV plus protons, either as recoil protons (dn) fromfast neutron interactions, largely with hydrogen, or from
neutron capture (dN) by nitrogen in tissue:
14N+ 1n = 14C+
1p + 580 keV. These various absorbed dose components,
contributing to the total radiation dose, are usually as-
sumed to act independently of each other. Thus the total
photon-equivalent dose(Dw) is given by the following
equation: Dw = (dγ ×DRF) + (dn × RBEn) + (dN × RBEN) +
(10B × CBE) where DRF is the dose reduction factor for
γ-rays, which varies with dose rate; RBEn is the relative
RBE of fast neutrons, which depends on neutron energy,
RBEN the equivalent value for protons from the nitro-
gen capture reaction and CBE, which is derived from
two factors: the RBE of α-particles and 7Li ions and the
microdistribution of 10B in a particular tissue. Due to
the short range of these particles in tissue, 9 and 5 μm,
respectively, the biological effect depends critically on
both the gross and microscopic distributions of 10B in tis-
sues (Hopewell et al. 2011; Hopewell et al. 2012; Coderre
et al. 2003).
Table 2 The values of relative biological effectiveness
and compound biological effectiveness factors
Total tumor cells Quiescent cells
<Surviving fraction = 0.01>
Neutrons only 2.65 ——
BPAa (250 mg/kg) 4.2 ——
BPA (500 mg/kg) 3.45 ——
BPA (750 mg/kg) 3.0 ——
BSHb (125 mg/kg) 3.4 ——
BSH (250 mg/kg) 3.15 ——
BSH (325 mg/kg) 3.0 ——
<Net micronucleus frequency = 0.7>
Neutrons only 2.85 5.1
BPA (250 mg/kg) 2.4 3.1
BPA (500 mg/kg) 2.15 2.8
BPA (750 mg/kg) 2.1 2.6
BSH (125 mg/kg) 2.25 3.3
BSH (250 mg/kg) 2.05 3.0
BSH (325 mg/kg) 2.0 2.9
a; Boronophenylalanine-10B.
b; Sodium mercaptododecaborate-10B.
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http://www.springerplus.com/content/3/1/128As Q cell populations have been shown to have a much
larger hypoxic fraction (HF) than total cell populations
(Masunaga and Ono 2002), and hypoxic cells are thought
to exhibit less uptake than aerobic cells (Masunaga and
Ono 2002; Masunaga et al. 2012), it follows that Q cells
have a lower uptake capacity than the total cell population,
that is, the distribution of 10B from 10B-carriers into Q
cells is less dependent on the uptake ability of the cells
than on the diffusion of the drugs. Further, taking into
consideration that the cellular distribution of 10B fromTable 3 Dose modifying factorsa for quiescent tumor cells
relative to the total tumor cell populations
Treatment
<Net micronucleus frequency = 0.7>
γ-Rays only 1.85 (1.7-2.0)b
Neutrons only 1.05 (1.0-1.1)
BPAc (250 mg/kg) 1.5 (1.4-1.6)
BPA (500 mg/kg) 1.55 (1.45-1.65)
BPA (750 mg/kg) 1.6 (1.5-1.7)
BSHd (125 mg/kg) 1.2 (1.15-1.25)
BSH (250 mg/kg) 1.3 (1.2-1.4)
BSH (325 mg/kg) 1.4 (1.3-1.5)
a; Radiation dose required to obtain the net normalized micronucleus
frequency of 0.7 in the quiescent tumor cell population in relation to the
radiation dose required to obtain a net normalized micronucleus frequency of
0.7 in total tumor cell population.
b; 95% confidence limit.
c; Boronophenylalanine-10B.
d; Sodium mercaptododecaborate-10B.BSH is more dependent on the diffusion of the drug,
whereas that from BPA is more dependent on the ability
of the cells to take up 10B, it was reasonable that the
values of CBE factors for BPA were higher than those
for BSH in the total tumor population, while in the Q
cell population, those for BPA were lower than those for
BSH. Consequently, as shown before (Ono et al. 1999;
Masunaga and Ono 2002), when 10B-carrier is employed
for the selective tumor cell-killing effect as a whole, the
combined use with BPA and BSH can be one of the prom-
ising techniques in BNCT.
Meanwhile, the increase in the 10B concentrations in
tumors did not keep pace with that in the concentra-
tions of the administered 10B-carriers. In other words,
the values of CBE factors showed a decreasing tendency
as the concentrations of the administered 10B-carriers
increased, especially in the Q tumor cell population
when BPA was employed. These were thought to be
partially due to the tumor heterogeneity. Especially, the
decrease in the values of CBE factors showed the diffi-
culty in the homogeneous distribution of 10B through-
out solid tumors, particularly in the Q cell population,
partially due to the degree of the tumor heterogeneity.
Thus, this may mean that the values of CBE factors can
reflect the level of tumor heterogeneity of solid tumors
(Hopewell et al. 2012; Hall 2012).
In BNCT, compared with reactor neutron beam irradi-
ation only, Q cells have been shown to have significantly
less radio-sensitivity than the total cell population when
a 10B-carrier, especially BPA, is employed (Table 3)
(Masunaga and Ono 2002; Masunaga et al. 2012). Thus,
more Q cells can survive BNCT than P cells. In addition,
when a 10B-carrier was used, this difference in the radio-
sensitivity between total and Q cell populations increased
as the concentrations of administered 10B-carriers in-
creased. This was also partially because the increase in dis-
tributing 10B from a 10B-carrier into the Q cell population
did not keep pace with that in the concentrations of the
administered 10B-carriers. In other words, intratumor
microenvironmental heterogeneity has a greater impact
on the 10B concentration in solid tumors as a higher
concentration of a 10B-carrier is administered. This also
means that a newly developed 10B-containing drug not
only should be non-toxic to normal cells but 10B from
the drug also has to be delivered as homogenously as
possible throughout the tumors over the intratumor
heterogeneity.
Tumor heterogeneity is now thought to be one of the
major difficulties in the treatment of solid tumors (Marusyk
et al. 2012; Bhatia et al. 2012). Many tumors contain pheno-
typically and functionally heterogeneous cancer cells. The
most well-established mechanism involves intrinsic differ-
ences among cancer cells caused by stochastic genetic or
epigenetic changes (clonal evolution). Differences can also
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http://www.springerplus.com/content/3/1/128arise among cancer cells through extrinsic mechanisms in
which different microenvironments within a tumor confer
phenotypic and functional differences upon cancer cells in
different locations (Magee et al. 2012). It is well known that
tumor vessels are characteristically dilated, saccular and
tortuous and exhibit large inter-endothelial cell junctions,
increased numbers of fenestrations and lack of normal
basement membrane. The abnormal structure of tumor
blood vessels compromise blood flow and hinder effective
convective fluid transport, resulting in the impaired distri-
bution of blood-borne therapeutic agents (Vaupel 2004).
Thus, increasing the dose of 10B compound might not be
effective however much drug is administered. Finally,
some cancers follow a stem cell model in which
tumorigenic cancer stem cells “differentiate” into nontu-
morigenic cancer cells, creating a hierarchical organization
(Bhatia et al. 2012). The differentiation of cancer stem
cells provides a mechanism for generating phenotypic and
functional heterogeneity beyond the heterogeneity that
can be attributed to clonal evolution or environmental dif-
ferences (Magee et al. 2012). Meanwhile, when the clinical
outcome of the Argentine cutaneous melanoma treat-
ments was assessed with regard to the doses derived from
the standard procedure, the use of fixed RBE values was
shown to have a formal inconsistency, which in practice
lead to unrealistically high tumor doses, and it was reported
that the fixed RBE approach was not suitable to understand
the observed clinical results in terms of the photon radio-
therapy data (Gonzalez and Santa Cruz 2012).
The CBE factor for each tissue and tumor, which was
shown to greatly depend on the degree of the possibility
for distributing 10B from a 10B-carrier, may be one of
promising candidates for the index for estimating tumor
heterogeneity. In the future, we would like to analyze the
CBE factor in details not only as a parameter in BNCT,
but also as a significant index for assessing intratumor
heterogeneity.
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